PTD-DBM
Also known as: PTD-DBM peptide, Protein Transduction Domain–Dishevelled Binding Motif, PTD-fused Dvl-binding motif, CXXC5-Dvl competitor peptide
Experimental; not approved anywhere; no published human trials found
5 notable studies · 6 references
TLDR
PTD-DBM is an experimental cell-penetrating peptide that blocks CXXC5, a natural brake on the Wnt/β-catenin pathway. In mouse studies from one Korean laboratory, it promoted hair regrowth, new follicle formation after wounding, faster and less-scarred wound healing, and bone-cell differentiation. It has not been tested in published human trials, and the long-term safety of keeping Wnt signaling switched on is unknown.
At a Glance
Classification: Synthetic cell-penetrating competitor peptide; inhibitor of the CXXC5–Dishevelled interaction; experimental Wnt/β-catenin pathway activator
PTD-DBM is an experimental peptide from Kang-Yell Choi's laboratory at Yonsei University in Seoul, South Korea. Researchers designed it to switch off a "brake" on the Wnt/β-catenin pathway. The Wnt/β-catenin pathway helps control hair-follicle cycling, wound repair, scarring and bone formation. The brake in question is a protein called CXXC5. When Wnt signaling turns on, CXXC5 binds a signaling hub protein called Dishevelled (Dvl) and dampens the signal, which is a negative-feedback loop. PTD-DBM has two parts: • DBM (Dishevelled-binding motif): the short part of CXXC5 that grabs Dishevelled, used here as a decoy • PTD (protein transduction domain): a cell-penetrating sequence that carries the decoy into cells. The decoy competes with the real CXXC5 for Dishevelled, which releases the brake and lets Wnt/β-catenin signaling stay active. It is studied mainly for: • Hair regrowth and androgenetic alopecia (male- and female-pattern hair loss) • Wound-induced hair-follicle regeneration • Cutaneous wound healing and reduced scarring • Bone formation (osteoblast differentiation). All published work is from cells, tissue explants and mice. No human clinical trial results were found in PubMed.
What Is PTD-DBM?
PTD-DBM is a synthetic fusion peptide, not a natural hormone or growth factor. CXXC5 → binds Dishevelled → suppresses Wnt/β-catenin PTD-DBM → occupies the CXXC5-binding site on Dishevelled → CXXC5 cannot suppress → Wnt/β-catenin stays active. The concept matters because CXXC5 levels are reported to be higher in balding human scalp follicles. Mice lacking CXXC5 show faster hair regrowth, faster wound healing and higher bone density. Choi is CEO of CK Regeon, a company licensed to develop this Wnt-activating approach, according to a conflict-of-interest statement in a 2023 paper. The same group has also developed small-molecule CXXC5–Dvl inhibitors, such as KY19382, which are different compounds.
What Are Researchers Studying?
Hair regrowth
A 2017 study found CXXC5 elevated in miniaturized hair follicles of human balding scalps. Disrupting the CXXC5–Dishevelled interaction with the competitor peptide activated Wnt/β-catenin signaling and accelerated hair regrowth in mice.
Androgenetic alopecia mechanisms
A 2023 mouse study proposed that DHT drives hair loss partly through prostaglandin D2 (PGD2), and PGD2 through CXXC5. PTD-DBM, or knocking out CXXC5, reversed PGD2-induced hair loss and restored new follicle formation after wounding. This is a mouse model of androgen-related hair loss, not a trial in people with pattern baldness.
Wound healing and scarring
CXXC5-knockout mice heal skin wounds faster. In wild-type mice, PTD-DBM plus valproic acid sped up wound healing. A 2023 study delivered PTD-DBM and valproic acid in an adhesive hydrogel patch and reported reduced scarring, stem-cell markers and collagen III patterns associated with regenerative, rather than fibrotic, healing.
Bone formation
CXXC5 also restrains osteoblast differentiation. A competitor peptide blocking the Dvl–CXXC5 interaction activated Wnt/β-catenin, promoted osteoblast differentiation, and sped thickness growth of cultured mouse skull bones. Later drug-development work in this area moved to small molecules.
How Does It Work?
PTD-DBM (enters cells via its PTD) ↓ binds Dishevelled at the site CXXC5 normally uses ↓ blocks CXXC5's negative feedback ↓ increased β-catenin signaling ↓ in hair follicles: dermal papilla activation and anagen (growth-phase) induction in wounds: more collagen and keratin production and new follicle formation in bone cells: osteoblast differentiation. Researchers often pair it with valproic acid, a GSK-3β inhibitor that activates the same pathway from a different point, and report stronger effects with the combination. A safety question the literature has not resolved: chronic Wnt/β-catenin activation is linked to some cancers, so long-term safety of sustained pathway activation is a real open question.
What Does the Research Show?
Human research
NOT ESTABLISHED No published human trials. Human-derived evidence includes balding scalp tissue showing higher CXXC5 and cultured human dermal papilla cells.
Animal research
MODERATE (single group) Mouse studies show hair regrowth, wound-induced hair neogenesis, faster wound healing, and reversal of hair loss induced by prostaglandin D2 and DHT. Almost all come from the Choi laboratory.
In-vitro research
MODERATE Cell studies support the mechanism in keratinocytes, fibroblasts, dermal papilla cells and osteoblasts.
Notable Studies
The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing
animalJournal: Journal of Experimental Medicine. Identified CXXC5 as a negative-feedback regulator of Wnt/β-catenin in skin. CXXC5-knockout mice healed wounds faster, and the competitor peptide PTD-DBM activated β-catenin and collagen production in cells. Combining PTD-DBM with valproic acid accelerated wound healing in mice.
Limitations: Mouse wounds heal differently from human wounds (mice heal largely by contraction). Single laboratory.
View publication →CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation
in-vitroJournal: Cell Death and Differentiation. CXXC5-deficient mice had higher bone mineral density. A competitor peptide blocking the Dvl–CXXC5 interaction activated Wnt/β-catenin signaling and osteoblast differentiation, and accelerated growth in thickness of skull bones cultured outside the body.
Limitations: Peptide effects shown in cells and explants. Bone-density gains in knockout mice do not show what the peptide does in living animals or humans.
View publication →Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis
animalJournal: Journal of Investigative Dermatology. CXXC5 was elevated in miniaturized follicles of human balding scalps and suppressed human dermal papilla cell activity. CXXC5-knockout mice showed faster hair regrowth, and the competitor peptide accelerated hair regrowth and wound-induced hair follicle neogenesis in mice.
Limitations: Mouse hair cycling differs from human pattern hair loss. Human data are tissue and cell observations, not treatment. Author affiliation with a company developing the approach.
View publication →CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2
animalJournal: Cells. Prostaglandin D2-induced hair loss in mice was reversed by CXXC5 knockout or PTD-DBM. PTD-DBM also overcame PGD2 suppression of wound-induced hair neogenesis. DHT-induced hair loss was reported to act through the PGD2–CXXC5 axis and was eased by blocking both GSK-3β and CXXC5.
Limitations: Mouse models of androgen- and PGD2-driven hair loss. The corresponding author is CEO of a company licensed to develop the approach.
View publication →Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment
animalJournal: Advanced Healthcare Materials. Hyaluronic-acid hydrogel patches loaded with PTD-DBM and valproic acid reduced scar formation in mouse wounds, lowered α-smooth muscle actin (a scarring marker), and raised stem-cell markers and collagen III, consistent with more regenerative healing.
Limitations: Combination delivery system in mice, so the peptide's own contribution is hard to isolate. No human data.
View publication →What We Still Don't Know
• Whether PTD-DBM regrows hair or improves wound healing in humans; no clinical trial results were found in PubMed • How well it penetrates intact human scalp skin when applied topically • Long-term safety of sustained Wnt/β-catenin activation, including tumor risk • Its exact sequence and formulation in any development product, which are not consistently stated in the abstracts • Effects without valproic acid in wound models • Independent replication outside the Choi laboratory • How it compares with established hair-loss treatments (minoxidil, finasteride).
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the PTD-DBM research with you.
Get the Aminodex PTD-DBM Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Lee SH, Kim MY, Kim HY, et al. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 2015;212(7):1061–1080.
- Kim HY, Yoon JY, Yun JH, et al. CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation. Cell Death Differ. 2015.
- Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY. Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesis. J Invest Dermatol. 2017;137(11):2260–2269.
- Ryu YC, Park J, Kim YR, et al. CXXC5 mediates DHT-induced androgenetic alopecia via PGD2. Cells. 2023;12(4):555.
- Lee SH, An S, Ryu YC, et al. Adhesive hydrogel patch-mediated combination drug therapy induces regenerative wound healing through reconstruction of regenerative microenvironment. Adv Healthc Mater. 2023;12(18):e2203094.
- Kim HY, Choi S, Yoon JH, et al. Small molecule inhibitors of the Dishevelled-CXXC5 interaction are new drug candidates for bone anabolic osteoporosis therapy. EMBO Mol Med. 2016. (Related small-molecule approach, not PTD-DBM.)
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.